InnoScience Proposes No 2025 Dividend, Seeks RMB1.01 Billion Subsidiary Guarantees and Fresh Share Mandates

Bulletin Express
04/30

InnoScience (Suzhou) Technology Holding Co., Ltd. has released the agenda for its Annual General Meeting (AGM) scheduled for 22 May 2026, outlining key operational, capital-management and governance resolutions.

Financial Highlights • 2025 performance remained loss-making; as a result, the Board recommends no profit distribution for the year. • Full 2025 financial statements and ESG disclosures have been published on HKEX and the company’s website for shareholder review.

Capital & Liquidity Measures • Subsidiary Guarantees: The company seeks shareholder approval to provide guarantees of up to RMB1.01 billion to support subsidiary production, operations and expansion. The aggregate limit can be used on a revolving basis through the conclusion of the 2026 AGM. • Issue Mandate: Directors request authority to issue up to 183.02 million new shares—equivalent to 20% of the existing issued share capital (excluding any treasury shares). • Repurchase Mandate: The Board also seeks capacity to buy back up to 52.55 million H shares, representing 10% of the current H-share float.

Audit & Fees • KPMG is nominated for re-appointment as external auditor for 2026. The audit fee is capped at RMB3.50 million, subject to final work scope.

Director Compensation • 2025 Actual Payments (selected executives): – Chairperson Dr. Weiwei Luo: RMB3.99 million (total) – CEO Dr. Wu Jingang: RMB5.46 million – CFO Mr. Zhong Shan: RMB2.39 million • 2026 Proposed Packages: – Dr. Luo: RMB4.61 million (salary + bonus) – Dr. Wu: RMB7.00 million – Mr. Zhong: RMB2.43 million – Non-executive directors will receive no base remuneration; independent non-executive directors to receive a monthly allowance of RMB40,000 before tax.

Shareholder Logistics • H-share register closes 19–22 May 2026; shareholders must lodge transfers by 18 May 2026 to vote. • Proxy forms must be submitted to Tricor Investor Services by 4:00 p.m. on 21 May 2026.

If approved, the mandates will grant the Board flexibility to raise capital, manage liquidity and support subsidiary growth while maintaining prudent oversight of audit and remuneration frameworks.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10